Immunome, Inc. (IMNM) Covered Calls
Immunome, Inc. (IMNM) is a clinical-stage biotechnology company focused on the discovery and development of targeted cancer therapies. The company utilizes a proprietary technology platform to identify novel antibody targets, with a primary focus on antibody-drug conjugates (ADCs) for oncology. By integrating data-driven discovery with clinical expertise, Immunome aims to develop first-in-class treatments that deliver precise, effective payloads to solid tumors.
You can sell covered calls on Immunome, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for IMNM (prices last updated Fri 4:16 PM ET):
| Immunome, Inc. (IMNM) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 20.36 | -0.63 | 19.90 | 20.40 | 952K | - | 2.4 |
| Covered Calls For Immunome, Inc. (IMNM) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 20 | 0.00 | 20.40 | -2.0% | -91.2% | |
| Apr 17 | 20 | 1.25 | 19.15 | 4.4% | 44.6% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Immunome, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cancer. By leveraging a unique, discovery-focused engine and deep understanding of human immune responses, the company identifies highly specific targets that can be addressed with potent, engineered antibody therapeutics.
Core Business and Pipeline
The company focuses on developing high-impact clinical assets that address significant unmet medical needs. Key elements of its pipeline include:
- Varegacestat: A late-clinical stage gamma-secretase inhibitor currently being evaluated for the treatment of desmoid tumors.
- IM-1021: A targeted antibody-drug conjugate (ADC) currently in clinical development, designed to leverage the company’s platform to deliver precise payloads to cancer cells.
- Discovery Platform: An integrated technology suite that combines deep-learning analytics with proprietary biology insights to accelerate the identification of novel therapeutic targets in oncology.
Competitive Landscape
Immunome operates within a highly competitive biotechnology sector, where clinical development speed and technological differentiation are essential. Notable competitors in the targeted oncology and ADC space that maintain active, liquid options markets include:
- ADC Leaders: Companies such as ADC Therapeutics and Pfizer (which possesses a massive oncology portfolio including ADCs).
- Oncology/Biotech Peers: Large-cap innovators like Eli Lilly or Merck, which frequently compete for oncology dominance through R&D and strategic M&A.
Strategic Outlook
Immunome’s strategic focus is to validate its lead assets while simultaneously scaling its discovery platform to generate a consistent pipeline of new drug candidates. By prioritizing high-efficacy oncology targets, the company seeks to build long-term value through internal development and potential strategic collaborations.
Looking ahead, the company aims to reach key regulatory and clinical milestones that demonstrate the safety and efficacy of its programs. With a robust approach to antibody engineering, Immunome is positioned to play a meaningful role in the evolution of targeted cancer care, providing essential solutions for patients with limited treatment options.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PL covered calls | |
| 3. | SPY covered calls | 8. | IWM covered calls | 3. | RCAT covered calls | |
| 4. | EEM covered calls | 9. | FXI covered calls | 4. | AXTI covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | LUNR covered calls | |
Want more examples? IMMR Covered Calls | IMO Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
